S&P 500
5.064,20 +45,81 (+0,91%) Nasdaq
15.840,96 +235,48 (+1,51%) NIKKEI 225
38.236,07 -37,98 (-0,10%) Dólar/Euro
1,0738 +0,0010 (+0,10%) Petróleo Brent
83,84 +0,17 (+0,20%) Bitcoin EUR
55.629,71 +2.279,53 (+4,27%)
Genmab A/S (GNMSF)
Genmab A/S
Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 2204
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO | 2,87M | N/A | 1961 |
| Mr. Anthony Pagano | Executive VP & CFO | 1,02M | N/A | 1978 |
| Ms. Birgitte Stephensen M.Sc. | Executive VP & Chief Legal Officer | 632,27k | N/A | 1961 |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer | 689,75k | N/A | 1971 |
| Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director | 114,96k | N/A | 1976 |
| Dr. Tahamtan Ahmadi | Executive VP, Chief Medical Officer & Head of Experimental Medicines | 1,11M | N/A | 1973 |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director | 158,07k | N/A | 1974 |
| Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director | 114,96k | N/A | 1975 |
| Mr. Anthony Mancini | Executive VP & COO | 1,09M | N/A | 1971 |
| Mr. Andrew Carlsen | Senior Director, VP & Head of Investor Relations | N/A | N/A | N/A |
Descripción
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Gobierno corporativo
El ISS Governance QualityScore de Genmab A/S, a día 1 de mayo de 2024, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 1; Derechos de los accionistas: 1; Compensación: 9.
